Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-07-14
2011-11-01
Kemmerer, Elizabeth C (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S009900, C530S351000, C530S402000
Reexamination Certificate
active
08048848
ABSTRACT:
A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
REFERENCES:
patent: 5177193 (1993-01-01), Boime
patent: 5759818 (1998-06-01), Boime et al.
patent: 5792460 (1998-08-01), Boime
patent: 6238890 (2001-05-01), Boime et al.
patent: 6514729 (2003-02-01), Bentzien
patent: 7094566 (2006-08-01), Medlock et al.
patent: 7141547 (2006-11-01), Rosen et al.
patent: 7371373 (2008-05-01), Shirley et al.
patent: 7553940 (2009-06-01), Fares et al.
patent: 7553941 (2009-06-01), Fares et al.
patent: 2003/0216313 (2003-11-01), Lustbader et al.
patent: 2007/0184530 (2007-08-01), Fares et al.
patent: WO 2005/080544 (2005-09-01), None
Weiss et al. Noncompliance in Neurologic Patients. Current Treatment Options in Neurology 7:419-425 (2005).
Furuhashi, M. et al; ‘Fusing the Carboxy-terminal Peptide of the Chorionic Gonadotropin (CG) β-Subunit to the Common a-Subunit: Retention of O-linked Glycosylation and Enhanced in vivo Bioactivity of Chimeric Human CG’ , Molecular Endocrinology, 1995, vol. 9, No. 1, pp. 54-63.
Furuhashi, M. et al, ‘Processing of O-linked Glycosylation in the Chimera Consisting of a-Subunit and Carboxyl-terminal Peptide of the Human Chorionic Gonadotropin β-Subunit is affected by Dimer Formation with Follicle-stimulating Hormone β-Subunit’, Endocrine Journal 2004, vol. 51, No. 1, pp. 53-59.
Schein, Catherine H. The shape of the messenger: using protein structure information to design novel cytokine-based therapeutics. Abstract; Current Pharmaceutical Design, vol. 8/No. 24, pp. 2113-2129 (2002).
Amirizahdeh et al. “Transient and stable expression of biologically active recombinant B-domain-deleted human factor VIII in mammalian cells” Journal of Sciences Islamic Republic of Iran; 16(2):103-112. Spring, 2005.
Boissel et al. “Erythropoietin structure-function relationships. Mutant proteins that test a model of tertiary structure” The Journal of Biological Chemistry,268, 15983-15993, Jul. 25, 1993.
Houdebine et al. “The methods to generate transgenic animals and to control transgene expression” Journal of Biotechnology vol. 98, Issues 2-3, pp. 145-160, Sep. 25, 2002.
Ngo et al. “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox” The protein folding problem and tertiary structure prediction. pp. 433-440 and 492-495. (1994).
Phillips et al. “The challenge of gene therapy and DNA delivery” Journal of Pharmacy and Pharmacology vol. 53, Issue 9, pp. 1169-1174, Sep. 2001, Abstract Only.
Unalp et al. “Factor VII deficiency associated with Valproate treatment” Pediatrics International vol. 50, Issue 3, pp. 403-405, Jun. 2008.
Wells. “Additivity of mutational effects in proteins” Biochemistry, 29 (37), pp. 8509-8517. (1990).
Weiss et al. “Noncompliance in neurologic patients” Curr Treat Options Neurol. Sep. 2005;7(5):419-23.
Fares Fuad
Fima Udi Eyal
Cohen Mark S.
Deberry Regina M
Kemmerer Elizabeth C
Pearl Cohen Zedek Latzer LLP
Prolor Biotech Ltd.
LandOfFree
Long-acting interferons and derivatives thereof and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Long-acting interferons and derivatives thereof and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Long-acting interferons and derivatives thereof and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4261034